Table 2.
The effects of BPF, CyC or BPF + CyC on liver injury parameters.
| Parameters | Placebo (n = 20) | BPF (n = 20) | CyC (n = 20) | BPF + CyC (n = 20) |
|---|---|---|---|---|
| ALP (U/L) | ||||
| Baseline | 64 ± 3.5 | 63 ± 5.1 | 64.5 ± 4.3 | 65.4 ± 5.6 |
| Δ16 weeks | −1.2 ± 0.7 | −12.3 ± 1.1 | - 15.2 ± 1,2 | −19.2 ± 1.85§ |
| GGT (U/L) | ||||
| Baseline | 66 + 3.7 | 66.2 ± 4.2 | 67.3 ± 3,8 | 68.3 + 4.3 |
| Δ16 weeks | - 2.73 ± 1.03 | - 15.2 ± 2,1 | - 15 ± 2.2 | −20.76 ± 2.4§ |
| ALT (U/L) | ||||
| Baseline | 56.4 + 4.6 | 55.3 ± 3.9 | 54 ± 4.4 | 54.8 + 4.7 |
| Δ16 weeks | −0.3 ± 0.6 | - 9 ± 1.1 | - 12 ± 1.8 | - 15.41 ± 2.6§ |
| AST (U/L) | ||||
| Baseline | 45.7 + 3.2 | 44.5 ± 3.8 | 43.2 ± 4,2 | 44.58 + 4.2 |
| 16 weeks | - 0.4 ± 0.69 | - 7 ± 1.9 | - 8 ± 1.8 | −18.23 ± 3.48§ |
| HA (ng/mL) | ||||
| Baseline | 86 + 6.8 | 87.4 ± 8,2 | 88.3 ± 6.8 | 82.6 ± 7.6 |
| Δ16 weeks | - 2.78 ± 3.21 | −16,6 ± 5,5 | −16.8 ± 4.1 | 21.6 ± 4.2§ |
| PC III (ng/mL) | ||||
| Baseline | 75.2 + 8.4 | 74.4 ± 6.4 | 76.2 ± 6.8 | 75.84 + 7.8 |
| Δ16 weeks | −1.9 ± 1.4 | −14.5 ± 2 | −16.5 ± 3.1 | −18.7 ± 3.4§ |
| IV-C (ng/mL) | ||||
| Baseline | 57.2 + 5.1 | 56.7 ± 5.1 | 57.6 ± 6.2 | 58.6 + 6.1 |
| Δ16 weeks | −1.57 ± 1.2 | −10 ± 3.1 | −13,1 ± 2,1 | −18.23 ± 3.48§ |
| Hepatorenal Index | ||||
| Baseline | 3.3 + 0.4 | 3.2 ± 0.6 | 3.3 ± 0.5 | 3.1 + 0.4 |
| Δ16 weeks | −0.3 + 0.1 | −1.1 ± 0.2 | 1.2 ± 0.3 | −1.6 + 0.3§ |
TB, total bilirubin; ALP, alkaline phosphatase; TP, total protein; GGT, gamma-glutamyltransferase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; HA, hyaluronic acid; PC-III, type III precollagen; IV-C, type IV collagen; Data are expressed as mean ± SD for each value; §P value of <0.05 between values at 16 week treatment with BPF + CyC compared to placebo group was taken as significant.